Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajiv Dixit

Rheumatology Walnut Creek, CA Medical Doctor

NPI 1396748158 CMS profile 245042

120 La Casa Via, Ste 204, Walnut Creek, CA 94598

Open in the dashboard

General payments

$12,213

568 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajiv Dixit of Walnut Creek, CA is reported in the CMS Open Payments database as having received $12,213 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $367 5
2024 General $447 6
2023 General $341 7
2022 General $2,433 102
2021 General $2,380 114
2020 General $2,988 150
2019 General $3,256 184

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajiv Dixit
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Rajiv Dixit were reported at $367. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Rajiv Dixit Rheumatology median Middle half National median
2019 $3,256 $744 $153–$2,687 $163
2020 $2,988 $462 $98–$2,027 $114
2021 $2,380 $531 $101–$2,153 $132
2022 $2,433 $627 $125–$2,303 $149
2023 $341 $741 $145–$2,524 $160
2024 $447 $830 $166–$2,660 $164
2025 $367 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $4,464 196 payments
  2. AbbVie, Inc. $1,313 47 payments
  3. Janssen Biotech, Inc. $884 50 payments
  4. Novartis Pharmaceuticals Corporation $663 37 payments
  5. UCB, Inc. $636 20 payments
  6. Pfizer Inc. $558 32 payments
  7. Horizon Therapeutics plc $508 29 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $439 7 payments
  9. E.R. Squibb & Sons, L.L.C. $277 17 payments
  10. GlaxoSmithKline, LLC. $273 15 payments
  11. Other $2,197 118 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,985 562 payments
  2. Education $228 6 payments
Products named General payments · program years 2019–2025
  1. Enbrel Inflammation $1,782 77 payments
  2. Otezla $1,526 69 payments
  3. Prolia $1,136 53 payments
  4. RINVOQ $770 23 payments
  5. EVENITY $724 30 payments
  6. SIMPONI ARIA $716 44 payments
  7. Enbrel Inflammation $696 35 payments
  8. COSENTYX $594 33 payments
  9. STELARA $493 32 payments
  10. XELJANZ $477 26 payments
  11. Other $7,025 351 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record